---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324917"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2026-07-30T11:38:04+00:00"
generated_at: "2026-07-30T11:40:06.527358+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences Q2 net loss $69.4M; WVE-007 Phase 2a dosing underway; FDA meeting for WVE-006

## Summary
- Net loss $69.4M vs $50.5M YoY; revenue $2.3M vs $8.7M; cash $490.6M, runway into 3Q 2028.
- WVE-007 (obesity) Phase 2a multidose dosing underway in BMI 35-50; combo/maintenance trials on track for 2H 2026.
- FDA meeting scheduled for end of summer 2026 to discuss accelerated approval for WVE-006 (AATD).
- WVE-008 (PNPLA3) CTA filing on track for 2H 2026; partnering discussions for HD and DMD programs.

## SEC filing metadata
- accession: 0001193125-26-324917
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2026-07-30T11:38:04+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/0001193125-26-324917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324917
- JSON: https://secwatch.observer/filing/0001193125-26-324917.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.